{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:16:29Z","timestamp":1792080989529,"version":"4.4.0"},"reference-count":18,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":7582,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1997,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There have been very few controlled studies of antidepressants in dysthymia, particularly in samples diagnosed reliably and with an adequate length of follow-up. In this investigation, we measured the long-term outcome in a large group of patients meeting DSM \u2013 III -R criteria for dysthymia. This study was designed to investigate whether fluoxetine is effective in the treatment of dysthymia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This randomised study, including 140 patients, compared fluoxetine (91 patients) and placebo (49 patients) on a double-blind basis in two distinct phases: a short-term end-point (3 months with 20 mg\/day fluoxetine) and a medium-term end-point (6 months) where the initial responders continued double-blind treatment unchanged and non-responders received an additional treatment of 20 mg\/day fluoxetine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After three months of treatment, response was seen more frequently in the fluoxetine group (42\/72) than in the placebo group (14\/39, P &lt;0.0001). Improved patients at 3 months were still improved at 6 months. Furthermore, 50% of the non-responders at 3 months improved and rated as responders at 6 months, after fluoxetine was increased to 40 mg daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study showed the significant and persistent action of fluoxetine on dysthymia. The finding that 50% of the non-responders at 3 months were improved at 6 months, after fluoxetine dosage was increased to 40 mg daily, argues in favour of treating dysthymic patients for at least 6 months, and with a higher dosage if the initial doses are ineffective.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.170.4.345","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:36:56Z","timestamp":1224049016000},"page":"345-350","source":"Crossref","is-referenced-by-count":58,"title":["Controlled efficacy study of fluoxetine in dysthymia"],"prefix":"10.1192","volume":"170","author":[{"given":"Jean-Marie","family":"Vanelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Attar-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bouhassira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Oli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"S0007125000146884_ref5","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1980"},{"key":"S0007125000146884_ref1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/ajp.140.1.11","article-title":"Dysthymic disorders: psychopathology of proposed chronic depressive subtypes","volume":"140","author":"Akiskal","year":"1983","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000146884_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb05877.x"},{"key":"S0007125000146884_ref10","volume-title":"Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0007125000146884_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(92)90111-Q"},{"key":"S0007125000146884_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(93)90110-8"},{"key":"S0007125000146884_ref2","first-page":"375","article-title":"La dysthymie et son traitement","volume":"19","author":"Akiskal","year":"1993","journal-title":"Enc\u00e9phale"},{"key":"S0007125000146884_ref3","first-page":"43","volume-title":"American Psychiatric Association Review","author":"Akiskal","year":"1992"},{"key":"S0007125000146884_ref6","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000146884_ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199504060-00005"},{"key":"S0007125000146884_ref12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1176\/ajp.150.8.1169","article-title":"A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia","volume":"150","author":"Hellerstein","year":"1993","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000146884_ref14","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1176\/ajp.147.12.1622","article-title":"Effects of pill-giving on maintenance of placebo response in patients with chronic mild depression","volume":"147","author":"Rabkin","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000146884_ref15","doi-asserted-by":"publisher","DOI":"10.1177\/070674379403900106"},{"key":"S0007125000146884_ref17","first-page":"815","article-title":"The epidemiology of dysthymia in five communities: rates, risks, comorbidity and treatment","volume":"145","author":"Weissman","year":"1960","journal-title":"American Jurnal of Psychiatry"},{"key":"S0007125000146884_ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.2.174"},{"key":"S0007125000146884_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/bs.3830190102"},{"key":"S0007125000146884_ref13","volume-title":"Schedule for Affective Disorders and Schizophrenia, Lifetime Version. Traduction et Adaptation Fran\u00e7aise","author":"Leboyer","year":"1992"},{"key":"S0007125000146884_ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000146884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T21:07:36Z","timestamp":1557608856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000146884\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["S0007125000146884"],"URL":"https:\/\/doi.org\/10.1192\/bjp.170.4.345","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,4]]}}}